ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,942.47
1.26%
Dow Jones
42,732.13
0.80%
US Dollar vs MXN
20.6314
0.01%
Brent Oil
76.495
0.00%
Bitcoin
98,229.51
0.13%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Madrigal Pharmaceuticals Inc (MDGL)

  7. Madrigal Pharmaceuticals Inc (MDGL) Noticias

MDGL

Madrigal Pharmaceuticals (MDGL)

Madrigal Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:MDGL
FechaHoraFuenteTítuloSímboloCompañía
03/01/202507:00GlobeNewswire Inc.Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MDGLMadrigal Pharmaceuticals Inc
22/11/202415:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
21/11/202415:30Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
14/11/202415:00Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
14/11/202405:30Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:MDGLMadrigal Pharmaceuticals Inc
06/11/202407:00GlobeNewswire Inc.Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor ConferencesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
31/10/202415:32Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MDGLMadrigal Pharmaceuticals Inc
31/10/202408:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
31/10/202406:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MDGLMadrigal Pharmaceuticals Inc
31/10/202406:00GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
30/10/202407:00GlobeNewswire Inc.Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®NASDAQ:MDGLMadrigal Pharmaceuticals Inc
21/10/202407:00GlobeNewswire Inc.Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH CirrhosisNASDAQ:MDGLMadrigal Pharmaceuticals Inc
18/10/202407:00GlobeNewswire Inc.Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024NASDAQ:MDGLMadrigal Pharmaceuticals Inc
02/10/202407:00GlobeNewswire Inc.Madrigal Pharmaceuticals to Participate in the H.C. Wainwright & Co. 8th Annual MASH Investor ConferenceNASDAQ:MDGLMadrigal Pharmaceuticals Inc
01/10/202407:00GlobeNewswire Inc.Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical DevelopmentNASDAQ:MDGLMadrigal Pharmaceuticals Inc
30/09/202407:00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces Publication of Positive Health-Related Quality of Life Results from the Phase 3 MAESTRO-NASH Trial of Rezdiffra™ (resmetirom)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
26/08/202407:00GlobeNewswire Inc.Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:MDGLMadrigal Pharmaceuticals Inc
15/08/202418:52Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
07/08/202406:00GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
02/08/202406:00GlobeNewswire Inc.Madrigal Pharmaceuticals Appoints Shannon Kelley as General CounselNASDAQ:MDGLMadrigal Pharmaceuticals Inc
24/07/202407:00GlobeNewswire Inc.Madrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024NASDAQ:MDGLMadrigal Pharmaceuticals Inc
06/06/202407:00GlobeNewswire Inc.Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL CongressNASDAQ:MDGLMadrigal Pharmaceuticals Inc
05/06/202407:00GlobeNewswire Inc.Madrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:MDGLMadrigal Pharmaceuticals Inc
29/05/202407:00GlobeNewswire Inc.Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL CongressNASDAQ:MDGLMadrigal Pharmaceuticals Inc
07/05/202415:34Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
07/05/202415:29Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MDGLMadrigal Pharmaceuticals Inc
07/05/202406:00GlobeNewswire Inc.Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:MDGLMadrigal Pharmaceuticals Inc
24/04/202415:00GlobeNewswire Inc.Madrigal Statement on the Passing of Dr. Stephen HarrisonNASDAQ:MDGLMadrigal Pharmaceuticals Inc
23/04/202407:00GlobeNewswire Inc.Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024NASDAQ:MDGLMadrigal Pharmaceuticals Inc
16/04/202415:05GlobeNewswire Inc.Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MDGLMadrigal Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MDGL

Su Consulta Reciente

NYSE
VZ
Verizon Communications
COIN
ADAUSD
Cardano
CCOM
US30
US 30
NYSE
XOM
Exxon Mobil
CCOM
SILVER
SILVER
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
AAPL
Apple
AMEX
XLV
Health Care Select Sector
NYSE
BAC
Bank of America
NASDAQ
AMZN
Amazon.com
AMEX
XLF
Financial Select Sector
COIN
SOLUSD
Solana
COIN
AVAXUSD
Avalanche
CCOM
OILBRENT
Brent Oil
USOTC
RHHBY
Roche (QX)
NYSE
CVX
Chevron
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados